A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: a case report

Rentao Yu 1, Yanzhi Guo 1, Yunjie Dan 1, Wenting Tan 1, Qing Mao 1,2* and Guohong Deng 1,2*

Abstract

Background: Butyrylcholinesterase (BChE), an ester hydrolase produced mainly by the liver, hydrolyzes certain short-acting neuromuscular blocking agents, like succinylcholine and mivacurium that are widely used during anesthesia. Patients with BChE deficiency are possibly in danger of postanesthetic apnea. Hereditary BChE deficiency results from the mutations of BCHE gene located on chromosome 3, 3q26.1-q26.2, between nucleotides 165,490,692-165,555,260.

Case presentation: This study describes a novel mutation in a child with BChE deficiency. In general, this child appeared healthy and well-developed with a normal appearance. However, the results of Wechsler Intelligence Scale showed that the full-scale intelligence quotient (FIQ) was 53, classified into the group with the minor defect. The BChE activity was 32.0 U/L, considerably lower than the normal lower limit (reference range: 5000-12,000 U/L). Sanger sequencing showed that there were 2 mutations in the exon 2 of BCHE gene of this child. One is a heterozygous mutation rs764588882 (NM_000055.3: c.401_402insA, p.Asn134Lysfs*23). The other one is a heterozygous mutation (NM_000055.3: c.73A > T, p.Lys25Ter) that has never been reported before. The two mutations lead to a premature stop of transcription.

Conclusions: Double heterozygous recessive mutations are the cause of BChE deficiency of this boy in this study, including a novel mutation c.73A > T. Intellectual disability is a new phenotype that is probably associated with this mutation.

Keywords: BCHE gene, Inherited butyrylcholinesterase deficiency, Genetic variant, Intellectual disability

Background

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are the two types of cholinesterases in humans [1]. Unlike AChE, BChE is an ester hydrolase produced mainly by the liver and then distributes to all tissues. Functionally, BChE hydrolyzes certain short-acting neuromuscular blocking agents, succinylcholine and mivacurium widely used during anesthesia, as well as some drugs like procaine, tetracaine and heroin [2]. Interestingly, patients with BChE deficiency have no life risks and are healthy in normal conditions. However, they are likely to be in danger of postanesthetic apnea, presenting as prolonged coma even death after the administration of succinylcholine or mivacurium [3, 4]. There are several factors that cause low BChE activity. Except for external factors, hereditary BChE deficiency may also lead to a low BChE activity in plasma.

In this paper, we describe a child with BChE deficiency identified by health examinations. Sanger sequencing identified a novel mutation that has never been reported. Besides, a novel phenotype presented by this child has not been described, either. We hope this report could provide new evidence and clues to the genetic variants and phenotype of BChE deficiency. This study was approved by the ethics committee of Southwest Hospital, Chongqing, China. Informed consents were obtained from his parents. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

* Correspondence: qingmao@yahoo.com; gh_deng@hotmail.com
1Department of Infectious Diseases, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Case presentation

This case was drafted and outlined in accordance with the CARE guidelines, which regulate the discipline of case reports. A 14-year-old boy, in his junior high school, visited the local hospital for routine physical examination. After regular biochemical examinations, we noticed an extremely low level of BChE activity for his liver function tests. Except for his parents, this child has a younger brother in the family. His four grandparents are still alive, but living in the remote district and did not come for tests. In general, this child appeared healthy and well-developed with a normal appearance. He had a soft abdomen and normal-sized liver with no tenderness and rebound tenderness. He had no other signs of liver injury or chronic liver disease. Based on his performance, Wechsler Intelligence Scale for Children (Chinese edition) was used for this child by qualified psychological doctor [5, 6]. The results showed that verbal intelligence quotient (VIQ) of this child was 51, and performance intelligence quotient (PIQ) was 57, and the full-scale intelligence quotient (FIQ) was 53. Finally, he was classified into the group with the minor defect based on the result. This is the first case report about the association between BChE deficiency and intellectual disability. The results of the remaining examination were normal.

Biochemical examinations revealed that this child had a normal blood level of aspartate aminotransferase (AST, 24.4 IU/L, reference range: 0-42 IU/L) and alanine aminotransferase (ALT, 27.4 IU/L, reference range: 0-42 IU/L) but an elevated blood level of alkaline phosphatase (ALP, 279 IU/L, reference range: 34-114 IU/L). The BChE activity was measured by means of colorimetric butyrylthiocholine with butyrylcholinesterase kit [7] at Hitachi 7600 chemistry auto-analyzer. Each step was conducted according to manufacturer’s instructions. The BChE activity was 32.0 U/L, considerably lower than the normal lower limit (reference range: 5000-12,000 U/L). Tests for hepatitis A virus (HAV) IgM antibodies, hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibodies (HBcAb), hepatitis C virus (HCV) antibodies were negative. The hepatitis B virus surface antibodies (HBsAb) were positive. Other laboratory examination results are shown in Table 1. Ultrasonography of the abdomen showed a normal result of each organ. The other members of his family had no critical abnormality and laboratory tests revealed normal results. The levels of BChE activity of each member are listed in Table 2.

To fully understand this abnormality, Sanger sequencing was applied to identifying potential variants that may affect BChE activity. He, his parents and his brother were withdrawn blood and then DNA was extracted for Sanger sequencing. Finally, the exonic regions of BCHE gene linked to BChE deficiency was chosen for sequencing in this family. The platform for Sanger sequencing is Applied Biosystems® 3730 DNA Analyzer by using BigDye™ Terminator v3.1 Cycle Sequencing Kit. BCHE gene contains 4 exons and 6 pairs of primers were designed and amplified at these four exons (Exon 2 is long and 3 pairs of primers were designed). The specific primer sequences and details of PCR are listed in Fig. 1. Table 2 shows the genetic variants identified by Sanger sequencing. There are 2 mutations in the exon 2 of BCHE gene of this child. One is a heterozygous mutation rs764588882 (NM_000055.3: c.401_402insA, p.Asn134Lysfs*23). The insertion of a base A introduces a frameshift mutation in the open reading frame, which results a stop Codon at the 23rd
amino acids downstream of the insertion point. The other variant is a novel heterozygous mutation (NM_000055.3: c.73A > T, p.Lys25Ter), which introduces a stop Codon at the same locus (stop at the 25th amino acid lysine). These two heterozygous mutations were also identified in his mother (c.401_402insA, p.Asn134Lysfs*23, heterozygous) and father (c.73A > T, p.Lys25Ter, heterozygous) respectively, suggesting that the two mutations distribute in the two chromosomes respectively. The exon 2 of BCHE gene in this child’s younger brother had no mutations in both of the two chromosomes. Combined with the serum BChE activity of his brother, we could reach to the hereditary pattern of this disorder in the family. As for exon 4, there are three single nucleotide polymorphisms (SNP) identified in this family, rs1803274 (NM_000055.3: c.1699G > A, p.Ala567Thr), rs3495 (NM_000055.3: 3’UTR *189G > A) and rs397762799 (NM_000055.3: 3’UTR *288-289insT), all of which are benign mutations as indicated by ClinVar database from National Center for Biotechnology Information (NCBI). Above all, it was the mutations in exon 2 but not exon 4 that caused BChE deficiency of this child. The electropherograms and sequencing results with comparison and hereditary pattern are shown in Fig. 2. Finally, this boy was diagnosed with hereditary BChE deficiency. Since this is a

| Subjects | BChE activity(U/L) | Exon 1 | Exon 2 | Exon 3 | Exon 4 |
|----------|--------------------|--------|--------|--------|--------|
| Father   | 8506.0             | None   | c.73A > T A/T, p.Lys25Ter, no report | None | 1) c.1699G > A G/A, p.Ala567Thr, rs1803274,1000G frequency:CHB(A = 16.99%)/CHS(A = 10.95%)*  
2) 3’UTR *189G > A G/A, rs3495,  
1000G frequency:CHB(A = 76.21%)/CHS(A = 78.57%)*  
3) 3’UTR *288-289insT T/T, rs397762799 |
| Mother   | 5003.0             | None   | c.401_402insA A/−, p.Asn134Lysfs*23, rs764588882 | None | 1) 3’UTR *189G > A A/A, rs3495,  
1000G frequency:CHB(A = 76.21%)/CHS(A = 78.57%)*  
2) 3’UTR *288-289insT T/T, rs397762799 |
| Brother  | 11,322.0           | None   | None   | None   | None |
| Patient  | 32.0               | None   | 1) c.73A > T A/T, p.Lys25Ter  
2) c.401_402insA A/−, p.Asn134Lysfs*23, rs764588882 | None | 1) 3’UTR *189G > A G/A, p.Ala567Thr, rs1803274, 1000G frequency:CHB(A = 16.99%)/CHS(A = 10.95%)*  
2) 3’UTR *189G > A A/A, rs3495,  
1000G frequency:CHB(A = 76.21%)/CHS(A = 78.57%)*  
3) 3’UTR *288-289insT T/T, rs397762799 |

*Population data were cited from the dbSNP database of NCBI

Fig. 1 The reagents, conditions and primers of PCR. a The components and volumes of PCR for BCHE gene. b The conditions of touchdown PCR. c The primer sequences of each exon of BCHE gene
benign disease and has no significant influence on the health of this boy, no specific medical interventions were applied to him, but he and his parents were told the risk of prolonged apnea after anesthesia.

Discussion and Conclusions

In summary, there are three types of causes that lead to reduced activity of BChE. The major cause is postnatal factors, especially the factors that induce liver injury. The most common reasons include liver and kidney disease, dystrophy, burn, malignancy, hypothermia, uremia and pregnancy [8–11]. The secondly dominant reason is drug-related factors. Some drugs have been reported to cause BChE deficiency and anticholinesterase drugs are the major types. Other drugs include contraceptive agents, glucocorticoid, monoamine oxidase inhibitor, esmolol, etc. [12] The remainder is genetic factors. This child had no signs of liver injury or severe diseases and he had never been administered these drugs, either. Consequently, we assume that this case belongs to the third category. Hereditary BChE deficiency results from the mutations of \( BCHE \) gene located on chromosome 3, 3q26.1-q26.2, between nucleotides 165,490,692–165,555,260 [13]. Over 20 genetic variants in \( BCHE \) gene have been identified to link with this type of disease, including qualitative variants with altered hydrolyzing activity, the atypical (A) [14], fluoride-resistant (F) [15], and silent (S) variants [16], etc. and quantitative variants with decreased enzyme concentration but normal activity, like H [17], J [18], and K variants [19].

In this study, we reported a new mutation that led to BChE deficiency. Despite that the mutations in \( BCHE \) gene are recessive, the double heterozygous recessive mutations of Exon 2, c.73A>T and c.401_402insA, occurred in the two chromosomes respectively caused the inactivity of BChE of this boy. Both mutations caused a precurrent stop of transcription, leading to a premature or inactive protein/ polypeptide.

Intellectual disability is the phenotype that was first found associated with BChE deficiency in our study. Although the exact mechanism still remains unknown, there did have been some studies implicating the possible connection. Animal experiments suggested that BChE together with AChE participates in the regulation of dorsal root ganglia, the growth of axons, nerve terminals and cones and other processes of neurite outgrowth [20]. Besides, BChE is reported to play a role in dementia and Alzheimer’s Disease (AD). In the mild AD, lower functional BChE levels in cerebrospinal fluid are linked to high Aβ-brain load and impaired cognitive performance. Especially, the K variants of BChE, which hinder the ability to interact with Aβ, is predominantly associated with the progression of AD [21]. Based on these previous studies, we assumed that there is an association between this new variant and the phenotype of intellectual disability. However, further studies should be conducted to confirm this connection.

Conclusively, double heterozygous recessive mutations are the cause of BChE deficiency of this boy in this study, including a novel mutation c.73A>T. Generally,
BChE deficiency is a benign disease, however, patients with BChE deficiency would be in danger of prolonged coma and respiratory depression. Besides, intellectual disability is another phenotype that probably should be considered and may be associated with this mutation. Based on this reason, it is important to determine the gene variants and heredity patterns. We hope that our findings could add new clues to this disease.

**Abbreviations**

AChE: Acetylcholinesterase; BChE: Butyrylcholinesterase; HBV: Hepatitis B virus; IQ: Intelligence quotient; SNP: Single nucleotide polymorphisms

**Acknowledgements**

We are grateful to the patient and his families for their collaboration.

**Funding**

This study was supported by National Natural Science Foundation grants (81330038), the Clinical Innovation Project from the Southwest Hospital (SWH2016ZDCX1007) and National Science and Technology Major Project of China (2017ZX1002303-002-003).

**Availability of data and materials**

Additional data that support the findings of this study are available from the corresponding author.

**Authors’ contributions**

Design of the work: QM, GD. Data collection: RY. Data analysis and interpretation: RY, YG, YD, WT. Manuscript preparation: RY. Manuscript revising, all authors. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Informed consent for this investigation was obtained from all participating patients and parents. As the patient was not an adult, his parents consented this research on behalf of this patient. The project was carried out in agreement with the Ethical Committee of the Southwest Hospital.

**Consent for publication**

Consent to publish from the parents to report their and their children’s medical information, sequencing results and family information has been obtained.

**Competing interests**

The funding sources had no role in study design, collection, analysis, or interpretation of data, or the writing of the report; or the decision to submit the report for publication.

GD is the associate editor of BMC Medical Genetics. Other authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Infectious Diseases, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, People’s Republic of China. 2Chongqing Key Laboratory of Infectious Diseases, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China.

Received: 5 December 2017 Accepted: 19 March 2018

**References**

1. Davis L, Britten JJ, Morgan M. Cholinesterase its significance in anaesthetic practice. Anaesthesia. 1997;52(3):244–60.

2. Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther. 2015;148(Supplement C):34–46.

3. Fisher DM. Neuromuscular blocking agents in paediatric anaesthesia. Br J Anaesth. 1999;83(1):58–64.

4. Gätke MR, Bundgaard JR, Vlby-Mogensen J. Two novel mutations in the BChE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia. Pharmacogenet Genomics. 2007;17(11):995–9.

5. Wechsler intelligence scale for children. In: Encyclopedia of autism Spectrum disorders. Edited by Volkmar FR. New York: Springer New York; 2013: 3346-3346.

6. Dan L, Yu J, Vandenberg SG, Yuemei Z, Caihong T. Report on shanghai patients and parents. As the patient was not an adult, his parents consented this research on behalf of this patient. The project was carried out in agreement with the Ethical Committee of the Southwest Hospital.

7. Garry PJ, Routh JI. A micro method for serum cholinesterase. Clin Chem. 1965;11(2):91–6.

8. Noro D, Koie T, Hashimoto Y, Tanaka T, Ohyama C, Tobisawa Y, Yoneyama T, Imai A, Hatakeyama S, Yamamoto H, et al. Significance of preoperative butyrylcholinesterase level as an independent predictor of survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. Jpn J Clin Oncol. 2017;1–6.

9. Moral-Naranjo MAT, Cabezas-Herrera J, Vidal CJ, Campoy FJ. Muscular dystrophy with laminin deficiency decreases the content of butyrylcholinesterase tetramers in sciatic nerves of Lama2dy mice. Neurosci Lett. 2002;331(3):155–8.

10. Han TH, Martyn JAJ. Neuromuscular pharmacodynamics of mivacurium in adults with major burns. Br J Anaesth. 2011;106(5):675–9.

11. Gruber M, Lindner R, Prasser C, Wiesner G. The effect of fluoride and hyperthermia on the in vitro metabolism of Mivacurium. Anesth Analg. 2002;95(2):397–9.

12. Zencirci B. Pseudocholinesterase enzyme deficiency: a case series and review of the literature. Cases journal. 2009;2:9148.

13. Nogueira CP, McGuire MC, Graesser C, Bartels CF, Arpagaus M, Van der Spek AF, Lightstone H, Lockridge O, La Du BN. Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG). Am J Hum Genet. 1990;46(5):934–42.

14. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajia A, Van der Spek AF, Lockridge O, La Du BN. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989;86(3):953–7.

15. Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, Lightstone H, Van der Spek AF, Lockridge O, La Du BN. Identification of two different point mutations associated with the fluoride-resistant phenotype for human butylycholinesterase. Am J Hum Genet. 1992;51(4):821–8.

16. Liddell J, Lehrmann H, Silk E. A ‘silent’ pseudo-cholinesterase gene. Nature. 1962;193:561–2.

17. Jensen FS, Bartels CF, La Du BN. Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families. Pharmacogenet. 1992;2(5):234–40.

18. Garry PJ, Dietz AA, Lubrano T, Ford PC, James K, Rubinstein HM, New allele at cholinesterase locus 1. J Med Genet. 1976;13(1):38–42.

19. Rubinstein HM, Dietz AA, Lubrano T, E1k, another quantitative variant at the cholinesterase locus 1. J Med Genet. 1978;15(1):27–9.

20. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4:131.

21. Lane RM, He Y. Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype. Alzheimers Dement. 2013;9(2):e17–73.